Previous 10 | Next 10 |
Final data from 93-patient Phase 2a clinical trial show lower annualized rate of vaso-occlusive crises (VOCs) and longer time to first VOC on IMR-687 Interim open-label extension clinical trial data through eight months show increased HbF response and continuation of lower VOC r...
Oral presentation provides final results from 93-patient Phase 2a trial and additional interim data from open label extension trial Imara to host conference call and live webcast on June 11, 2021 at 8:00 a.m. ET BOSTON, June 04, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq:...
Imara, Inc. (IMRA) Q1 2021 Earnings Conference Call April 11, 2021 08:30 ET Company Participants Michael Gray - Chief Financial Officer & Chief Operating Officer Rahul Ballal - President, Chief Executive Officer & Director Conference Call Participants Yigal Nochomovitz - Citigroup Mat...
Imara (IMRA): Q1 GAAP EPS of -$0.58 beats by $0.25.Cash, cash equivalents and investments were $75.6 million as of March 31, 2021.Press Release For further details see: Imara EPS beats by $0.25
On-track to report interim analyses for both Ardent sickle cell disease and Forte beta-thalassemia Phase 2b clinical trials in the second half of 2021 Completed enrollment in the transfusion-dependent beta-thalassemia arm of the Forte Phase 2b trial Higher dose arms open...
BOSTON, May 04, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin, today announced that the company wil...
IMARA Inc. (NASDAQ:IMRA) traded at a new 52-week low today of $6.63. So far today approximately 219,000 shares have been exchanged, as compared to an average 30-day volume of 135,000 shares. In the past 52 weeks, shares of IMARA Inc. have traded between the current low of $6.63 and a hig...
IMARA Inc. (NASDAQ:IMRA) traded at a new 52-week low today of $6.95. Approximately 219,000 shares have changed hands today, as compared to an average 30-day volume of 136,000 shares. There is potential upside of 14.6% for shares of IMARA Inc. based on a current price of $7.01 and an aver...
IMARA Inc. (NASDAQ:IMRA) traded at a new 52-week low today of $7.49. This new low was reached on above average trading volume as 219,000 shares traded hands, while the average 30-day volume is approximately 132,000 shares. IMARA Inc. share prices have moved between a 52-week high of $62....
BOSTON, March 29, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin, today announced that applications ...
News, Short Squeeze, Breakout and More Instantly...
IMARA Inc. Company Name:
IMRA Stock Symbol:
NASDAQ Market:
-- Combined Company to Trade on Nasdaq Under Ticker “ELVN” -- -- Imara Announces 1-for-4 Reverse Stock Split of Common Stock -- BROOKLINE, Mass., Feb. 22, 2023 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA) today announced the results of the special meeting of its stock...
There are plenty of ways to find the best penny stocks to buy. The first step, however, is knowing your idea of “best.” Everyone has a different style of trading and investing they subscribe to. Some look for entry opportunities to buy penny stocks and hold them long-term. O...
Insiders Play The Stock Market Game With Penny Stocks Want to find penny stocks to buy? How about trying the “Follow The Money” trend? It’s becoming more popular lately, especially in light of the recent stock market game being played. One day markets are up; th...